Arthritis, Juvenile Rheumatoid Clinical Trial
Official title:
Single Patient Use of Tocilizumab for Treatment of Steroid Dependent, Active Systemic Onset Juvenile Idiopathic Arthritis
The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA). Another purpose is to see if tocilizumab helps reduce the amount of steroids (prednisone) needed to control symptoms of soJIA.
Systemic onset Juvenile Idiopathic Arthritis (soJIA) is a type of arthritis (inflammation of
the joints) that occurs with other symptoms including fever, swollen lymph nodes (glands),
rash, and body aches. Because soJIA can be difficult to treat, children with soJIA can have
severe problems from long-term use of steroids (prednisone). These problems include low bone
density (weak bones), fractures, failure to grow properly, and large weight gain. The
arthritis that occurs in soJIA often causes damage to many joints. This can make it hard to
move around or do basic tasks like dressing. Also, a life-threatening illness called
Macrophage Activation Syndrome (MAS) can occur when starting, stopping, or changing drugs
that are used to treat soJIA.
SoJIA can be hard to treat and many children with soJIA do not respond to drugs that work
for other kinds of arthritis. Research doctors have studied a chemical signal called IL-6
that the body uses to manage inflammation. This signal has been found to be very high in
patients with active soJIA. A drug called tocilizumab (TCZ) has been designed to block IL-6.
For about 6 years, TCZ has been tested in Japan for treating soJIA. It is now being tested
in studies in the United States. These studies can have very strict rules for enrolling
patients. This trial is a single-patient research study for a subject who otherwise does not
meet the rules for enrollment in ongoing trials.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00807846 -
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
|
Phase 4 | |
| Completed |
NCT00279747 -
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
|
Phase 3 | |
| Completed |
NCT00652925 -
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
|
Phase 3 | |
| Completed |
NCT02001844 -
Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA
|
N/A | |
| Completed |
NCT00731965 -
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis
|
Phase 4 | |
| Completed |
NCT02067962 -
Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing
|
N/A | |
| Terminated |
NCT00637780 -
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
|
Phase 4 | |
| Completed |
NCT00001614 -
The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis
|
Phase 1 | |
| Completed |
NCT01412021 -
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
|
||
| Enrolling by invitation |
NCT02377245 -
Juvenile Inflammatory Rheumatism (JIR) Cohorte
|
||
| Completed |
NCT00426218 -
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1/Phase 2 | |
| Completed |
NCT00034853 -
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
|
Phase 3 | |
| Completed |
NCT06000566 -
Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
|
||
| Terminated |
NCT00511329 -
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
|
Phase 2/Phase 3 | |
| Terminated |
NCT00688545 -
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
|
||
| Recruiting |
NCT00012506 -
The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis
|
Phase 3 |